Shares of Altimmune, Inc. (NASDAQ:ALT – Get Free Report) shot up 9.8% during trading on Monday . The company traded as high as $3.05 and last traded at $2.9650. Approximately 1,219,605 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 4,213,115 shares. The stock had previously closed at $2.70.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on ALT. Leerink Partners assumed coverage on shares of Altimmune in a research report on Monday. They issued an “outperform” rating and a $10.00 price objective for the company. Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Truist Financial assumed coverage on Altimmune in a report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price target for the company. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Friday, March 27th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.71.
View Our Latest Stock Report on ALT
Altimmune Trading Up 8.0%
Altimmune (NASDAQ:ALT – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. On average, analysts forecast that Altimmune, Inc. will post -0.69 earnings per share for the current year.
Hedge Funds Weigh In On Altimmune
A number of hedge funds have recently bought and sold shares of ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Altimmune by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after purchasing an additional 2,241 shares during the period. Geneos Wealth Management Inc. acquired a new stake in Altimmune during the first quarter worth approximately $50,000. Envestnet Asset Management Inc. grew its position in Altimmune by 48.0% during the second quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock worth $127,000 after buying an additional 10,671 shares in the last quarter. Creative Planning increased its stake in Altimmune by 30.2% during the 2nd quarter. Creative Planning now owns 41,164 shares of the company’s stock worth $159,000 after acquiring an additional 9,558 shares during the period. Finally, Rhumbline Advisers increased its stake in Altimmune by 7.0% during the 2nd quarter. Rhumbline Advisers now owns 113,981 shares of the company’s stock worth $441,000 after acquiring an additional 7,462 shares during the period. 78.05% of the stock is owned by institutional investors.
Altimmune Company Profile
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
Read More
- Five stocks we like better than Altimmune
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
- 5 Stocks Solving the AI Power Crisis
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
